Genelux said a platinum-relapsed small cell lung cancer patient treated with Olvi-Vec primed immunochemotherapy saw an 84.6% tumor reduction and 16.7 months of progression-free survival. The data come from a single case report, underscoring both promise and limits.
published
Genelux said a platinum-relapsed small cell lung cancer patient treated with Olvi-Vec primed immunochemotherapy saw an 84.6% tumor reduction and 16.7 months of progression-free survival. The data come from a single case report, underscoring both promise and li
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.